The Cancer Letter

Inside information on cancer research and drug development

Vol.
35
No.
7
July 27, 2012Jul 27, 2012
Free
DOWNLOAD THE PDF

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer

Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints

Upper Endoscopy Most Effective When Performed in 3-Year Intervals

Women Who Concieve Using Fertility Drugs Have a Higher Risk Of Breast Cancer Than Non-Users

Variation in Breast Density May Be Strong Risk Factor

Study: Molecular Breast Imaging Can Be As Effective as MRI

Mammography Had Limited Impact Among Swedish Women Age 40-69

High Vitamin E Consumption Can Lower Liver Cancer Risks

Gene Expression Test Accurately Classifies “Inconclusive” Samples

CAP, ASCCP Recommendations Standardize Lesion Terminology

NCI-Approved CTEP Trials For The Month of July

Login

Looking for IP Login?